Bristol-myers Squibb Compnay

Mary Struthers

Ginger Chao Rakestraw

Stanley Richard Krystek, Jr

Akbar Nayeem

Aaron Yamniuk

Jonathan Harry Davis

Aaron Paul Yamniuk

Priyanka Apurva Madia

Michael Louis Doyle

Suzanne J Suchard

Stanley R Krystek

The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodies

Antagonistic CD40 monoclonal antibodies and uses thereof

Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

Nucleic acids encoding antagonistic CD40 monoclonal antibodies

Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R&#x3b1;), wherein IL2 or IL2R&#x3b1; comprises at least one fewer glycosylation site compared to native IL2 or native IL2R&#x3b1;. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use

Antagonistic CD40 monoclonal antibodies and uses in treating immune responses

Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity

Growing community of inventors

Edison, NJ, United States of America

Mary Struthers